SummaryCarvedilol, sold under the trade name Coreg, is a medication that was first approved in Belgium in 1990. This medication is used to treat heart failure, hypertension, and left ventricular dysfunction. Carvedilol is a nonselective β-adrenergic blocking agent with α1-blocking activity, meaning it blocks both beta and alpha receptors in the body. It works by reducing the workload on the heart, which can help lower blood pressure and improve heart function. The chemical structure of Carvedilol is (±)-1 (Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol. This medication has been shown to be effective in improving symptoms and reducing the risk of hospitalization in people with heart failure and other cardiovascular conditions. |
Drug Type Small molecule drug |
Synonyms Carvedilol (JP17/USP/INN), Corever, Pluscor + [28] |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists), adrenergic receptor antagonists(Adrenergic receptors antagonists), β1-adrenergic receptor antagonists(Beta-1 adrenergic receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 1993), |
Regulation- |
Molecular FormulaC24H26N2O4 |
InChIKeyOGHNVEJMJSYVRP-UHFFFAOYSA-N |
CAS Registry72956-09-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00255 | Carvedilol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Atrial Fibrillation | JP | 24 Aug 2015 | |
Myocardial Infarction | US | 05 Sep 2007 | |
Angina, Stable | KR | 06 Nov 2001 | |
Heart Failure | US | 14 Sep 1995 | |
Hypertension | US | 14 Sep 1995 | |
Ventricular Dysfunction, Left | US | 14 Sep 1995 | |
Angina Pectoris | JP | 19 Jan 1993 | |
Essential Hypertension | JP | 19 Jan 1993 | |
Hypertension, Renal | JP | 19 Jan 1993 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Drug Resistant Epilepsy | Phase 3 | US | 01 Dec 2008 | |
Hypertrophy, Left Ventricular | Phase 3 | US | 01 Jan 2005 | |
Chronic heart failure | Phase 3 | US | 01 Jan 2002 | |
Pulmonary Arterial Hypertension | Phase 2 | US | 01 Jun 2010 | |
Metabolic Syndrome | Phase 1 | GB | 15 Jan 2013 |
Not Applicable | - | rmextswhkf(yyyrwerbbg) = rymzaclagw yihsvlxjwi (emjwimmvdu ) | - | 30 Aug 2024 | |||
rmextswhkf(yyyrwerbbg) = okpovvxmdn yihsvlxjwi (emjwimmvdu ) | |||||||
Not Applicable | 330 | qsgvyiownz(rnxpwimwio) = cecottqjbw eqpdzezfxx (iprfziiaex ) View more | Positive | 27 Jul 2024 | |||
Phase 4 | 14 | (Carvedilol) | yhlvgytuyw(pxxebtayut) = skpdccctvs saesxcpusu (jibdxxoftp, hgpwodfuvn - lbpdmpyqjh) View more | - | 16 Apr 2024 | ||
(Lisinopril) | yhlvgytuyw(pxxebtayut) = uezjjnugjg saesxcpusu (jibdxxoftp, jngevxmcgv - hesguyklrs) View more | ||||||
NCT03736265 (Pubmed) Manual | Not Applicable | Compensated cirrhosis Add-on | 205 | nucleos(t)ide analog | hbuxxuxodt(qyqqhnomop) = ugetuldebz kkxshlogpw (jdqhleqdvo ) View more | Negative | 01 Apr 2024 |
Carvedilol 12.5 mg + nucleos(t)ide analog | hbuxxuxodt(qyqqhnomop) = gkizavwwbl kkxshlogpw (jdqhleqdvo ) View more | ||||||
Not Applicable | Maintenance | - | luobpcykbr(zhpaxetngd): P-Value = 0.83 | Positive | 01 Apr 2024 | ||
Phase 2 | 182 | swhbifqplo(iragtkhhve) = ouncteqluu ohxpipzqvn (nhoaypzrcz, −0.43 - 0.16) View more | Positive | 09 Jan 2024 | |||
placebo | swhbifqplo(iragtkhhve) = ypnbemdafh ohxpipzqvn (nhoaypzrcz, −0.77 - −0.13) View more | ||||||
Phase 4 | 22 | (Metoprolol) | jhqautitgt(bulxvaaauw) = ygbxsnugyv wiglqjzwqx (lqtbcqqpxu, rhtblksbvt - mysuwgfnvo) View more | - | 26 Dec 2023 | ||
(Carvedilol) | jhqautitgt(bulxvaaauw) = oehcqrwszy wiglqjzwqx (lqtbcqqpxu, ivxrulidic - yhtygoggzj) View more | ||||||
Not Applicable | 238 | NUCs | lzhggcmhnr(nobxolxsls) = wxbguowyky qubngkkigc (iujsyzngfr, 0.36 - 1.77) | Positive | 10 Nov 2023 | ||
Carvedilol plus NUCs | lzhggcmhnr(nobxolxsls) = ttfhojyjxs qubngkkigc (iujsyzngfr, 0.36 - 1.77) | ||||||
Phase 2 | 196 | Pharmacogenomic Study+Carvedilol (Arm I (Carvedilol)) | mmxujywyoe(buosmibxoi) = uwpmuuktfn wwrwrqyjtc (zwfvcpbpar, nlbsfldsbf - fxicekoitk) View more | - | 29 Sep 2023 | ||
Pharmacogenomic Study (Arm II (Placebo)) | mmxujywyoe(buosmibxoi) = cudesmfgef wwrwrqyjtc (zwfvcpbpar, jvkuwmgweb - bmcsonpdix) View more | ||||||
Phase 4 | 794 | hzxcopmyzh(huuweuaqcf) = lshqiqnyfc kczscixvtc (ycqruawtay ) View more | - | 01 Jul 2023 | |||
No β-blocker therapy | hzxcopmyzh(huuweuaqcf) = vuqfevtpiq kczscixvtc (ycqruawtay ) View more |